What question did this study set out to answer?

Provide a comprehensive clinical framework for recognizing, diagnosing, and managing transthyretin amyloid cardiomyopathy to optimize outcomes through early targeted intervention.

January 1, 2023Global HeartOpen Access

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

View Full Paper

Ask AI

Bookmark

Authors

DBDulce BritoWest Virginia University FAFabiano Castro AlbrechtInstituto Dante Pazzanese de Cardiologia DADiego Pérez de ArenazaHospital Italiano de Buenos Aires

Discussion

Member takes

Implication

Expert consensus outlines diagnostic pathways and management strategies in transthyretin amyloid cardiomyopathy, highlighting early detection and specialized multidisciplinary care.

Key Points

Provide a comprehensive clinical framework for recognizing, diagnosing, and managing transthyretin amyloid cardiomyopathy to optimize outcomes through early targeted intervention.
Convened an international panel of 18 specialist clinicians across 13 countries alongside a patient advocacy representative from the Amyloidosis Alliance.
Synthesized evidence from peer-reviewed literature, patient registries, expert clinical insights, and patient-reported priorities regarding diagnostic pathways and novel therapies.
Identified cardiac involvement as the critical determinant of clinical prognosis, necessitating prompt phenotypic evaluation across both hereditary and wild-type forms.
Determined that novel disease-modifying therapies yield maximal therapeutic efficacy when administered during early disease stages, underscoring the necessity of specialized amyloidosis centers.

Cite This Study

Brito et al. (2023) studied this question.

synapsesocial.com/papers/6a87bd3cf762332bf8fe787f https://doi.org/10.5334/gh.1262

View Full Paper

Ask AI

Bookmark

Implication

Expert consensus outlines diagnostic pathways and management strategies in transthyretin amyloid cardiomyopathy, highlighting early detection and specialized multidisciplinary care.

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Discussion

Member takes

Implication

Key Points

Cite This Study

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider